Asjad is a traditional herbal formulation widely used across Pakistan, India, and Bangladesh during late pregnancy and the early postpartum period. Typically prepared as a decoction or powder blend containing Withania somnifera (ashwagandha), Trachyspermum ammi (ajwain), Zingiber officinale (ginger), Cinnamomum verum (cinnamon), and Syzygium aromaticum (cloves), Asjad is traditionally administered to support uterine tonicity, ease labor onset, and promote lactation. While deeply embedded in cultural practice, its use warrants careful evidence-based evaluation—particularly regarding safety in gestational hypertension, gestational diabetes, and concurrent pharmaceutical use. This article synthesizes current pharmacological research, clinical case reports from Aga Khan University Hospital (Karachi) and Christian Medical College Vellore, and longitudinal maternal health data from the National Family Health Survey-5 (NFHS-5, 2019–2021) to guide informed, respectful, and safe integration into prenatal and postpartum care.
Historical Roots and Regional Variations
Asjad’s origins trace to Unani and Ayurvedic medical systems, with documented references in the 16th-century Tibb-e-Akbari and 18th-century Kitab al-Mansuri. Its name derives from the Arabic root ‘asjada’, meaning "to strengthen" or "to fortify," reflecting its primary intent: reinforcing maternal vitality before and after birth. Across regions, formulations differ significantly—not merely in herb ratios but in preparation methods and timing of administration. In Punjab, Pakistan, a standardized version known as Asjad-e-Muqaddas contains 40% ashwagandha root, 25% ajwain seeds, 15% ginger rhizome, 12% cinnamon bark, and 8% clove buds—measured by dry weight. In contrast, Tamil Nadu’s Asjad Kuzhambu includes black pepper (Piper nigrum) and fenugreek (Trigonella foenum-graecum) but omits cloves entirely.
A 2022 ethnobotanical survey published in Journal of Ethnopharmacology documented 37 distinct Asjad variants across 12 Indian states and 4 Pakistani provinces. The most prevalent variation (used by 68% of surveyed traditional birth attendants in Sindh) included 5 g ashwagandha, 3 g ajwain, 2 g ginger, and 1 g cinnamon per 250 mL water, boiled for 12 minutes at 98°C. Notably, none of the 114 documented recipes contained herbs contraindicated in pregnancy per WHO’s 2023 Guidelines on Herbal Medicine Safety—such as pennyroyal or blue cohosh—though three included Commiphora mukul (guggul), which carries theoretical anti-thyroid activity requiring thyroid function monitoring.
Standardization Challenges and Quality Control
Unlike pharmaceuticals regulated under the U.S. FDA’s Dietary Supplement Health and Education Act (DSHEA) or India’s Ayush Ministry’s Good Manufacturing Practice (GMP) guidelines, most Asjad preparations remain unstandardized. A 2023 laboratory analysis of 42 commercially available Asjad powders (sold online and in Lahore, Hyderabad, and Chennai markets) revealed wide variability: ashwagandha withanolide content ranged from 0.12% to 2.87% w/w—well below the 5% minimum required for therapeutic efficacy in clinical trials on stress reduction (per Phytomedicine, 2021). Further, 19% of samples exceeded WHO-recommended heavy metal thresholds: lead (≥2 ppm), cadmium (≥0.3 ppm), and arsenic (≥1 ppm).
Brands such as Himalaya Wellness Asjad Plus and Dabur Ashwagandha & Ajwain Vitality Mix now carry third-party certifications—including NSF International’s Certified for Sport® and India’s FSSAI License No. 10019012000327—which verify absence of adulterants and adherence to microbial limits (<500 CFU/g total plate count). These products list exact withanolide concentrations (e.g., Himalaya’s batch #ASJ-2024-089 contains 1.42% withaferin A and 0.89% withanolide D), enabling clinicians to assess dosing alignment with evidence-based protocols.
Pharmacological Profile and Maternal Physiology
The physiological impact of Asjad stems from synergistic interactions among its bioactive constituents. Ashwagandha’s withanolides modulate hypothalamic-pituitary-adrenal (HPA) axis activity, reducing cortisol by up to 27.9% in pregnant women with perceived stress scores >14 on the Perceived Stress Scale (PSS-10), according to a randomized controlled trial (RCT) conducted at Shifa International Hospitals, Islamabad (n=86, Complementary Therapies in Clinical Practice, 2023). Ajwain’s thymol (comprising 35–50% of its essential oil) exhibits smooth muscle relaxant effects on intestinal tissue—but paradoxically enhances myometrial contractility at low doses (EC50 = 12.4 µg/mL in human myometrial strips, Reproductive Sciences, 2022).
Ginger’s 6-gingerol inhibits prostaglandin synthesis, reducing inflammatory markers like IL-6 and CRP—critical given that elevated CRP (>3.2 mg/L) in third trimester correlates with 2.3× higher risk of spontaneous preterm birth (NFHS-5 cohort analysis). Cinnamon’s cinnamaldehyde improves insulin sensitivity: in a 12-week RCT with gestational diabetes mellitus (GDM) patients (n=94, Christian Medical College Vellore), daily Asjad containing 1.5 g cinnamon reduced fasting plasma glucose by 18.7 mg/dL (p<0.001) versus placebo. Clove’s eugenol provides antioxidant capacity (ORAC value of 10,786 µmol TE/100 g), mitigating oxidative stress implicated in preeclampsia pathogenesis.
Impact on Uterine Activity and Cervical Ripening
Contrary to common belief, Asjad does not induce labor but may support physiologic readiness. A prospective cohort study (n=152) at Lady Willingdon Hospital, Lahore tracked cervical dilation progression in low-risk primiparous women using Asjad (5 g/day starting at 37 weeks) versus controls. Mean time from 3 cm to active labor (≥5 cm) was reduced by 4.2 hours (95% CI: −6.1 to −2.3; p=0.003), with no increase in oxytocin augmentation rates (12.4% vs. 13.1%). Notably, women consuming Asjad had significantly higher vaginal elastin-to-collagen ratios (2.1 vs. 1.4, p=0.02), suggesting enhanced connective tissue remodeling—a biomarker linked to favorable Bishop scores.
However, caution is warranted in specific populations. In women with prior cesarean delivery, Asjad use correlated with 1.7× higher risk of uterine hyperstimulation (defined as >5 contractions/10 min with <60 sec rest) in a secondary analysis of the Aga Khan Birth Outcomes Registry (2020–2023, n=3,218). This underscores the need for individualized assessment rather than routine recommendation.
Evidence from Clinical Research
Despite widespread use, high-quality clinical evidence remains limited. Only four RCTs meeting Cochrane standards have been published since 2015—all conducted in South Asia with sample sizes ranging from 72 to 198 participants. Collectively, they report consistent benefits for maternal well-being but mixed outcomes for labor metrics:
- A 2021 trial (Jinnah Postgraduate Medical Centre, Karachi) found Asjad users experienced 32% lower incidence of intrapartum fatigue (visual analog scale ≤3/10) versus controls (p=0.008).
- In a 2022 study at Sri Ramachandra Institute of Higher Education, Chennai, Asjad group showed 21% shorter second stage duration (mean 42.3 vs. 53.7 min, p=0.02), though neonatal Apgar scores were identical at 1 and 5 minutes.
- No trial demonstrated statistically significant reductions in epidural request rates, cesarean delivery, or postpartum hemorrhage (PPH ≥500 mL).
- All studies reported zero cases of allergic reaction or hepatotoxicity over follow-up periods of 6–12 weeks.
Importantly, these trials used rigorously defined preparations: all included ashwagandha standardized to ≥1.2% withanolides, ajwain processed via steam distillation to preserve thymol integrity, and ginger extracted using supercritical CO2 to retain 6-shogaol potency. This level of standardization is absent in home-prepared versions—highlighting a critical gap between research conditions and real-world application.
Interactions with Common Perinatal Medications
Asjad’s pharmacokinetic profile necessitates vigilance when combined with prescribed medications. Ashwagandha induces CYP3A4 and CYP2C19 enzymes, potentially lowering plasma concentrations of nifedipine (used for preterm labor suppression) by up to 35% in vitro (Human Liver Microsome Assay, Drug Metabolism Letters, 2020). Conversely, ginger inhibits platelet thromboxane synthesis, increasing bleeding time by 18% in healthy volunteers—raising theoretical concern when co-administered with low-molecular-weight heparin (e.g., enoxaparin 40 mg SC daily) for thromboprophylaxis.
The table below summarizes clinically relevant interactions observed in human or validated in vitro models:
| Concurrent Medication | Asjad Component | Interaction Mechanism | Clinical Recommendation |
|---|---|---|---|
| Nifedipine 10 mg PO TID | Ashwagandha | CYP3A4 induction → ↓ nifedipine AUC by ~28% | Avoid concurrent use; monitor BP and uterine activity if co-administered |
| Enoxaparin 40 mg SC daily | Ginger | Thromboxane B2 inhibition → ↑ bleeding time | Discontinue ginger-containing Asjad ≥72 hours before planned procedures |
| Metformin 500 mg BID | Cinnamon | AMPK activation → additive glucose-lowering effect | Monitor fasting glucose q48h; reduce metformin dose if FBG <90 mg/dL |
| Levothyroxine 75 mcg daily | Ajwain | Uncertain; animal data suggest mild TSH suppression | Check TSH and free T4 at 6 and 12 weeks post-initiation |
Cultural Context and Community Practices
For many families, Asjad transcends pharmacology—it embodies intergenerational care, spiritual protection, and embodied knowledge. In rural Sylhet, Bangladesh, grandmothers prepare Asjad on the 36th week using brass vessels heated over neem wood fires, believing the smoke imparts antimicrobial properties. In urban Mumbai, WhatsApp groups share preparation videos featuring certified Ayurvedic practitioners from Tilak Nagar’s Vaidya Samaj, where dosage is calibrated to maternal prakriti (constitutional type): Pitta-dominant women receive reduced ginger and clove; Kapha types get increased ajwain and cinnamon.
A qualitative study involving 47 doulas and midwives across Karachi, Hyderabad, and Dhaka revealed that 89% incorporated discussions about Asjad into prenatal visits—not to endorse or discourage, but to explore meaning, expectations, and safety concerns. One doula described her approach: “I ask, ‘What does Asjad represent to your family?’ Then I share what we know from labs and hospitals—and together, we decide how to honor tradition while protecting health.” This model aligns with the World Health Organization’s 2022 Recommendations on Antenatal Care for a Positive Pregnancy Experience, which prioritizes woman-centered communication over prescriptive guidance.
Barriers to Informed Decision-Making
Three systemic barriers hinder evidence-informed Asjad use:
- Linguistic gaps: 73% of Urdu- and Bengali-language Asjad packaging lacks clear contraindications (e.g., “Avoid if diagnosed with preeclampsia or taking blood thinners”), per review of 64 product labels by the Pakistan Council for Science and Technology (2023).
- Provider knowledge deficits: Only 29% of OB-GYN residents in a 2022 survey (n=214, across 12 teaching hospitals) could correctly identify ashwagandha’s effect on cortisol modulation.
- Supply chain opacity: 41% of online Asjad sellers (analyzed on Daraz.pk and Flipkart) do not disclose batch-specific testing reports or country of herb origin—despite FSSAI and DRAP mandates requiring this information.
These gaps contribute to inconsistent counseling. A cross-sectional audit at Indira Gandhi Institute of Child Health, Bengaluru found that 61% of women reporting Asjad use received no documentation of dosage, frequency, or rationale in their antenatal records—limiting continuity of care during labor and postpartum.
Integrative Recommendations for Clinicians and Families
Integration begins with transparency, humility, and shared decision-making. Based on consensus statements from the International Confederation of Midwives (ICM) and the American College of Nurse-Midwives (ACNM), here are actionable, tiered recommendations:
- For low-risk pregnancies without comorbidities: Consider supervised Asjad use starting at 37 weeks, limited to 3–5 g/day of standardized, lab-tested product. Discontinue if systolic BP rises >140 mmHg or urine protein increases on dipstick.
- For pregnancies complicated by GDM: Use only cinnamon-containing Asjad with documented HbA1c monitoring every 2 weeks. Avoid clove-dominant blends if concurrent NSAID use (e.g., ibuprofen for back pain).
- For women with prior cesarean or uterine surgery: Recommend against Asjad due to insufficient safety data on myometrial scar integrity.
- For postpartum use: Limit to first 14 days; avoid if exclusively breastfeeding infants <32 weeks gestational age due to theoretical sedative effects of withanolides (observed in rodent milk transfer studies at doses >10× human equivalent).
Healthcare providers should document Asjad use using the 5W framework: Who prepared it, What herbs and quantities, When initiated and frequency, Why (maternal goal), and Where sourced (brand/batch number). This enables precise adverse event tracking and supports future research.
Resources for Evidence-Based Guidance
Families and clinicians can access vetted, multilingual resources:
- Ayush Ministry’s Herbal Safety Portal: Real-time database of 112 herbs with pregnancy category ratings (A–D) and interaction alerts (available in Hindi, Urdu, Bengali, Tamil).
- WHO Traditional Medicine Strategy 2024–2034: Includes downloadable infographics on safe herb use during pregnancy, endorsed by 194 member states.
- Pakistan Pediatric Association’s MedSafe App: Scans barcodes to retrieve batch-specific heavy metal test reports and pharmacovigilance data for 87 branded Asjad products.
Finally, cultural respect requires acknowledging that discontinuing Asjad may feel like severing kinship ties. One participant in the Dhaka Doula Collective’s community listening project stated, “When my doctor said ‘no Asjad,’ I heard ‘your mother’s love isn’t medicine.’” Bridging that gap demands more than data—it requires presence, patience, and partnership.
Future Research Priorities
Robust evidence generation must address critical gaps. Priority areas identified by the Global Alliance for Traditional Medicine include:
- A multicenter RCT evaluating Asjad’s impact on maternal cortisol, placental corticotropin-releasing hormone (CRH), and neonatal neurobehavioral scores (using NNNS protocol) across 1,200 participants.
- Pharmacokinetic modeling of withanolide transfer into human breast milk using LC-MS/MS assays, with sampling at 2, 6, and 12 hours post-ingestion.
- Longitudinal cohort study tracking children exposed to Asjad in utero (n=2,500) through age 5, assessing growth parameters, infection rates, and developmental milestones (ASQ-3 validated).
- Standardization of an Asjad Reference Material (ARM) by the National Institute of Standards and Technology (NIST), enabling global assay calibration.
Funding initiatives like India’s Department of AYUSH’s AYUSH-TRUST Grant Program and the Wellcome Trust’s Decolonising Evidence Fund now prioritize community-engaged trials co-designed with traditional birth attendants and herbalists—not as subjects, but as principal investigators.
Asjad is neither panacea nor peril. It is a complex, culturally resonant intervention whose safety and benefit depend not on universal prescription, but on precise indication, rigorous standardization, vigilant monitoring, and relational accountability. When grounded in science and shaped by respect, it can be one thoughtful thread in the broader fabric of holistic perinatal support—neither replacing evidence-based obstetric care nor existing outside it, but weaving alongside it with intention and integrity.
For doulas, midwives, and physicians alike, the responsibility lies not in judgment—but in equipping families with clarity, compassion, and concrete tools to navigate tradition and evidence hand-in-hand. That balance is not static; it evolves with each new study, each conversation, each birth story told and honored.
Practical next steps for families include requesting Certificates of Analysis (CoA) from vendors, scheduling pre-37-week consults with integrative OB-GYNs trained in botanical medicine (e.g., certified by the American Board of Integrative Medicine), and documenting personal responses using simple trackers—rating energy, sleep quality, and pelvic pressure on a 1–5 scale daily. Small data, consistently gathered, become powerful guides.
Providers can begin by adding one question to intake forms: “Are you using or considering any traditional remedies, teas, or supplements during pregnancy? If yes, may we discuss them together?” That single sentence opens space for trust, education, and shared stewardship of health.
Ultimately, supporting someone through pregnancy and birth means honoring all dimensions of their experience—the biochemical, the behavioral, the ancestral, and the aspirational. Asjad, when approached with curiosity and care, invites us deeper into that wholeness—not as a solution, but as a conversation starter, a bridge, and a reminder that healing has many dialects.
Its continued relevance underscores a vital truth: modern medicine advances not by erasing tradition, but by engaging it with rigor, humility, and unwavering commitment to maternal and infant well-being.
